CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer

Wolfgang Hilbe, Ufuk Abacioglu, Daniel M. Aebersold, Mounir Bachouchi, Thomas Brodowicz, Rabab Gaafar, Gerold Holzer, Andrea Mohn-Staudner, Dimitar Kalev, Ewa Kalinka-Warzocha, Viljem Kovac, Marco Siano, Fulden Yumuk, L. Tamási

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Skeletal-related events represent a substantial burden for patients with advanced cancer. Randomized, controlled studies suggested superiority of denosumab over zoledronic acid in the prevention of skeletal-related events in metastatic cancer patients, with a favorable safety profile. Experts gathered at the 2012 Skeletal Care Academy in Istanbul to bring forward practical recommendations, based on current evidence, for the use of denosumab in patients with bone metastases of lung cancer. Recommendations: Based on current evidence, use of denosumab in lung cancer patients with confirmed bone metastases is recommended. It is important to note that clinical judgment should take into consideration the patient's general performance status, overall prognosis, and live expectancy. Currently, the adverse event profile reported for denosumab includes hypocalcemia and infrequent occurrence of osteonecrosis of the jaw. Therefore, routine calcium and vitamin D supplementation, along with dental examination prior to denosumab initiation are recommended. There is no evidence for renal function impairment due to denosumab administration. At present, there is no rationale to discourage concomitant use of denosumab and surgery or radiotherapy.

Original languageEnglish
Pages (from-to)75-82
Number of pages8
JournalMemo - Magazine of European Medical Oncology
Volume6
Issue number2
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Lung Neoplasms
Neoplasm Metastasis
Bone and Bones
zoledronic acid
Osteonecrosis
Hypocalcemia
Denosumab
Jaw
Vitamin D
Neoplasms
Tooth
Radiotherapy
Calcium
Kidney
Safety

Keywords

  • Bone metastases
  • Denosumab
  • Lung cancer
  • RANK ligand
  • Skeletal-related events

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. / Hilbe, Wolfgang; Abacioglu, Ufuk; Aebersold, Daniel M.; Bachouchi, Mounir; Brodowicz, Thomas; Gaafar, Rabab; Holzer, Gerold; Mohn-Staudner, Andrea; Kalev, Dimitar; Kalinka-Warzocha, Ewa; Kovac, Viljem; Siano, Marco; Yumuk, Fulden; Tamási, L.

In: Memo - Magazine of European Medical Oncology, Vol. 6, No. 2, 06.2013, p. 75-82.

Research output: Contribution to journalArticle

Hilbe, W, Abacioglu, U, Aebersold, DM, Bachouchi, M, Brodowicz, T, Gaafar, R, Holzer, G, Mohn-Staudner, A, Kalev, D, Kalinka-Warzocha, E, Kovac, V, Siano, M, Yumuk, F & Tamási, L 2013, 'CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer', Memo - Magazine of European Medical Oncology, vol. 6, no. 2, pp. 75-82. https://doi.org/10.1007/s12254-013-0088-6
Hilbe, Wolfgang ; Abacioglu, Ufuk ; Aebersold, Daniel M. ; Bachouchi, Mounir ; Brodowicz, Thomas ; Gaafar, Rabab ; Holzer, Gerold ; Mohn-Staudner, Andrea ; Kalev, Dimitar ; Kalinka-Warzocha, Ewa ; Kovac, Viljem ; Siano, Marco ; Yumuk, Fulden ; Tamási, L. / CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer. In: Memo - Magazine of European Medical Oncology. 2013 ; Vol. 6, No. 2. pp. 75-82.
@article{534558a71a8448a39d2053c05f7ad8e1,
title = "CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer",
abstract = "Purpose: Skeletal-related events represent a substantial burden for patients with advanced cancer. Randomized, controlled studies suggested superiority of denosumab over zoledronic acid in the prevention of skeletal-related events in metastatic cancer patients, with a favorable safety profile. Experts gathered at the 2012 Skeletal Care Academy in Istanbul to bring forward practical recommendations, based on current evidence, for the use of denosumab in patients with bone metastases of lung cancer. Recommendations: Based on current evidence, use of denosumab in lung cancer patients with confirmed bone metastases is recommended. It is important to note that clinical judgment should take into consideration the patient's general performance status, overall prognosis, and live expectancy. Currently, the adverse event profile reported for denosumab includes hypocalcemia and infrequent occurrence of osteonecrosis of the jaw. Therefore, routine calcium and vitamin D supplementation, along with dental examination prior to denosumab initiation are recommended. There is no evidence for renal function impairment due to denosumab administration. At present, there is no rationale to discourage concomitant use of denosumab and surgery or radiotherapy.",
keywords = "Bone metastases, Denosumab, Lung cancer, RANK ligand, Skeletal-related events",
author = "Wolfgang Hilbe and Ufuk Abacioglu and Aebersold, {Daniel M.} and Mounir Bachouchi and Thomas Brodowicz and Rabab Gaafar and Gerold Holzer and Andrea Mohn-Staudner and Dimitar Kalev and Ewa Kalinka-Warzocha and Viljem Kovac and Marco Siano and Fulden Yumuk and L. Tam{\'a}si",
year = "2013",
month = "6",
doi = "10.1007/s12254-013-0088-6",
language = "English",
volume = "6",
pages = "75--82",
journal = "Memo - Magazine of European Medical Oncology",
issn = "1865-5041",
publisher = "Springer Wien",
number = "2",

}

TY - JOUR

T1 - CECOG experts' recommendations on the use of denosumab in the prevention of skeletal-related events in bone metastases of lung cancer

AU - Hilbe, Wolfgang

AU - Abacioglu, Ufuk

AU - Aebersold, Daniel M.

AU - Bachouchi, Mounir

AU - Brodowicz, Thomas

AU - Gaafar, Rabab

AU - Holzer, Gerold

AU - Mohn-Staudner, Andrea

AU - Kalev, Dimitar

AU - Kalinka-Warzocha, Ewa

AU - Kovac, Viljem

AU - Siano, Marco

AU - Yumuk, Fulden

AU - Tamási, L.

PY - 2013/6

Y1 - 2013/6

N2 - Purpose: Skeletal-related events represent a substantial burden for patients with advanced cancer. Randomized, controlled studies suggested superiority of denosumab over zoledronic acid in the prevention of skeletal-related events in metastatic cancer patients, with a favorable safety profile. Experts gathered at the 2012 Skeletal Care Academy in Istanbul to bring forward practical recommendations, based on current evidence, for the use of denosumab in patients with bone metastases of lung cancer. Recommendations: Based on current evidence, use of denosumab in lung cancer patients with confirmed bone metastases is recommended. It is important to note that clinical judgment should take into consideration the patient's general performance status, overall prognosis, and live expectancy. Currently, the adverse event profile reported for denosumab includes hypocalcemia and infrequent occurrence of osteonecrosis of the jaw. Therefore, routine calcium and vitamin D supplementation, along with dental examination prior to denosumab initiation are recommended. There is no evidence for renal function impairment due to denosumab administration. At present, there is no rationale to discourage concomitant use of denosumab and surgery or radiotherapy.

AB - Purpose: Skeletal-related events represent a substantial burden for patients with advanced cancer. Randomized, controlled studies suggested superiority of denosumab over zoledronic acid in the prevention of skeletal-related events in metastatic cancer patients, with a favorable safety profile. Experts gathered at the 2012 Skeletal Care Academy in Istanbul to bring forward practical recommendations, based on current evidence, for the use of denosumab in patients with bone metastases of lung cancer. Recommendations: Based on current evidence, use of denosumab in lung cancer patients with confirmed bone metastases is recommended. It is important to note that clinical judgment should take into consideration the patient's general performance status, overall prognosis, and live expectancy. Currently, the adverse event profile reported for denosumab includes hypocalcemia and infrequent occurrence of osteonecrosis of the jaw. Therefore, routine calcium and vitamin D supplementation, along with dental examination prior to denosumab initiation are recommended. There is no evidence for renal function impairment due to denosumab administration. At present, there is no rationale to discourage concomitant use of denosumab and surgery or radiotherapy.

KW - Bone metastases

KW - Denosumab

KW - Lung cancer

KW - RANK ligand

KW - Skeletal-related events

UR - http://www.scopus.com/inward/record.url?scp=84881368270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881368270&partnerID=8YFLogxK

U2 - 10.1007/s12254-013-0088-6

DO - 10.1007/s12254-013-0088-6

M3 - Article

AN - SCOPUS:84881368270

VL - 6

SP - 75

EP - 82

JO - Memo - Magazine of European Medical Oncology

JF - Memo - Magazine of European Medical Oncology

SN - 1865-5041

IS - 2

ER -